Append Medical Overview
Append Medical has developed a minimally invasive implantable device designed to reduce stroke risk in patients suffering from atrial fibrillation. The Append Medical system is designed to prevent blood clot leakage by achieving complete LAA closure thus reducing the risk of stroke in patients with non-valvular atrial fibrillation. Its unique design may allow it to mitigate device-related thromboembolism risk by leaving minimal foreign material at the closure site. The Left Atrial Appendage exclusion technology was invented by Dr. Leonid Sternik and developed at Sheba Medical Center, further licensed by Append Medical. The company is a portfolio company of MEDX Xelerator.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Append Medical Raises $4.35M in Initial Closing of Extended Series A
Append Medical, an Israel-based medical device company, has raised $4.35 million in an extended Series A funding round. The funds will be used to complete the development of and support the First-in-Human Study of the Appligator™, a device designed to prevent stroke in atrial fibrillation patients by closing the left atrial appendage (LAA) without requiring any metal implants. Investors included Shoni Health Ventures and ALIVE Israel HealthTech Fund, along with participants from the first tranche of the A round.
Investment
growth-positive
Append Medical Completes $7.4M Million Series A Round
Append Medical has completed a $7.4 million Series A financing round, which will enable the company to complete development and perform its first clinical trial. The company has developed a no-implant minimally invasive solution for transcatheter Left Atrial Appendage (LAA) exclusion, aimed at reducing stroke risk in atrial fibrillation patients. The financing round was led by an unnamed strategic company and MedTecX LP, along with other investors. The company was founded in 2017 and is a member of MEDX Xelerator, a med-tech incubator formed as a collaboration between Boston Scientific, Intellectual Ventures, MEDX Ventures, and Sheba Medical Center.
Investment
growth-positive
https://www.jpost.com/health-science/israeli-company-soon-to-begin-trial-on-stroke-risk-reduction-device-649063
Israeli medical start-up Append Medical has been given special permission to present their technology to help atrial fibrillation patients. The companys device, called The Appligator, is designed to seal the Left Atrial Appendage without an implant, reducing the risk of stroke. Append Medical completed its first pre-clinical chronic procedure and is preparing for the first human trials. The company received validation for its approach from IMMR, a Paris-based company that helps conduct pre-clinical studies.
PartnersInvestment
growth-positive
https://www.jpost.com/opinion/hillels-tech-corner-append-medical-takes-the-unknown-out-of-strokes-632840
Append Medical, a medical device company, has developed a minimally invasive device called the Appligator™ to reduce stroke risk in patients with atrial fibrillation. The device aims to close the left atrial appendage (LAA), which is a breeding ground for blood clots that can cause strokes. The LAA closure market is projected to reach $958 million by 2025. Append Medical has received funding from MEDX Xelerator, with investments from Boston Scientific, MEDX Ventures, Intellectual Ventures, and the companys founder and CEO, Zachi Berger. The company recently conducted successful clinical trials for its device, and it is supported by a strong scientific advisory board. Despite being a relatively small company, Append Medicals technology shows promise in addressing a significant global health risk.
Customers
growth-positive
Append Medical shares clinical proof-of-concept results for internal sealing of LAA
Append Medical and Sheba Medical Center have announced clinical proof-of-concept data for Appends Appligator LAA closure device. The device aims to minimize stroke risk in atrial fibrillation patients by completely closing the left atrial appendage. The procedure utilizes natural tissue manipulation to achieve closure, leaving only a suture to seal the area. The clinical safety trials have shown efficacy in LAA closure and the approach can simplify the procedure, making it safer and more effective. Append Medicals device is designed to accelerate the shift from blood thinners to transseptal interventions for stroke risk reduction in AF patients.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $12.55M |
| Last funding | $4.35M |
| Stage | A |
| Rounds | 3 |
| Investors | 6 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | appendmedical.com |
Locations
Ariel Sharon Boulevard 8, Or Yehuda, Israel
Photos & Videos
1 item(s)
